Journal September 26, 2026 6 min read

Which peptides are studied in relation to continuous glucose monitoring?

Continuous glucose monitoring appears in research as a measurement tool across drug, device and dietary studies. This page maps the compounds and interventions studied alongside CGM, and states plainly where the evidence

peptides-pro Editorial

Continuous glucose monitoring (CGM) is a method of tracking interstitial glucose over time rather than at isolated fingerstick points. In the research literature it appears less often as a subject in its own right than as an outcome-measurement instrument attached to a compound, device or behavioural intervention. The compounds studied in relation to CGM in the evidence summarised here are not peptides in the classical sense: they are small-molecule oral antidiabetics (dorzagliatin, metformin, linagliptin), an injectable peptide hormone analogue (insulin glargine), a dopamine-receptor agonist used in veterinary endocrinology (cabergoline), and non-pharmacological interventions including time-restricted eating and structured exercise. No sequence, molecular formula or molecular weight is supplied in the evidence block for any of these, so none is stated here.

The mechanistic work centres on glucose-sensing and glucose-lowering pathways: glucokinase activation at the pancreatic and hepatic level, biguanide action on hepatic glucose output and insulin sensitivity, GLP-1 receptor-independent incretin comparison via DPP-4 inhibition, and exogenous insulin receptor signalling. CGM is the common readout across these otherwise unrelated mechanisms.

Research Studies

Dorzagliatin and glycemic homeostasis in type 2 diabetes with chronic renal insufficiency

A prospective, randomized, active-controlled, multicentre study is planned to enrol 206 patients with type 2 diabetes mellitus complicated by moderate to severe chronic renal insufficiency, defined as an estimated glomerular filtration rate below 45 mL/min/1.73 m². The trial compares dorzagliatin with linagliptin for glycemic control. After screening, participants enter a two-week run-in of diet and exercise control together with continuous glucose monitoring [1]. The CGM component sits inside the run-in rather than as the primary endpoint, which is worth noting when reading the protocol.

Insulin glargine dosing frequency and glucose time in range in pregestational diabetes

A randomized study in pregnant patients with pregestational diabetes assigns participants to once-daily or twice-daily insulin glargine. Continuous glucose monitoring is used to track blood glucose, and the primary question is whether twice-daily dosing produces better glucose time in range [4]. This is a direct comparison of two dosing schedules of the same peptide hormone analogue, with CGM supplying the continuous outcome.

Metformin interruption and metabolic flexibility in metabolic syndrome

A clinical trial investigates how a short-term interruption of metformin affects insulin sensitivity, glucose control and metabolic flexibility in adults with metabolic syndrome already taking the drug as part of usual care. The interruption period is 14 days, and the study asks whether glucose metabolism changes rapidly or whether prior metformin effects persist during the gap [6]. The rationale given is real-world: missed doses, access problems, travel, or planned short-term discontinuation.

Accu-Chek SmartGuide CGM with the Predict App in type 1 and insulin-treated type 2 diabetes

A controlled pre-post trial tests a CGM system and its predictive features in adults with type 1 diabetes or insulin-treated type 2 diabetes. The questions concern fear of hypoglycemia, sleep quality, confidence in preventing hypoglycemia, diabetes-related distress, diabetes empowerment, and whether predictive features change glucose levels and device use [7]. Here the CGM system is the intervention under study rather than a passive measurement tool.

Time-restricted eating and weight-loss maintenance

A multi-centre two-arm randomized controlled trial across six regions in China targets overweight or obese adults who have recently lost at least 5% of body weight. It evaluates whether a 10-hour daily time-restricted eating regimen prevents weight regain more effectively than standard weight-maintenance counselling, with both arms receiving the same frequency and intensity of nutritional counselling [8].

Rowing exercise and multilevel physiological response

An observational study of 30 members of the Polish Youth National Rowing Team, aged 19–24, examines physiological, molecular, metabolic, intestinal, immunological and psychophysiological responses to rowing-specific exercise across two training periods, including a 2000-m maximal ergometer effort [5]. The stated focus includes mitochondrial function, metabolic regulation, intestinal permeability, immune activation and DNA damage response.

Continuous glucose monitoring versus self-monitoring in gestational diabetes

A study compares CGM with self-monitoring of blood glucose in women with gestational diabetes mellitus, a condition first diagnosed during pregnancy. The protocol notes risks including macrosomia, delivery complications, increased likelihood of insulin treatment and higher risk of high blood pressure during pregnancy, and frames good blood sugar control as the means of reducing them [2].

Chronic pancreatitis cohort with longitudinal ERCP

The BILE-CP study is a prospective longitudinal cohort in Hangzhou, Zhejiang Province, China, planning to enrol 1,500 patients with chronic pancreatitis for follow-up every six months, with in-depth tracking of a sub-cohort undergoing ERCP. Multidimensional data collected at baseline and follow-up include sociodemographics, diet and lifestyle, emotional status and sleep [3].

Cabergoline, pituitary tumour shrinkage and diabetic remission in cats

Two cats with diabetes mellitus and Cushing syndrome are described. Diabetes was initially managed with insulin glargine, nutritional therapy and continuous glucose monitoring; hypercortisolism was suspected on the basis of severe hypertension in one case and insulin resistance in the other, and cabergoline treatment was associated with pituitary tumour shrinkage and diabetic remission [10]. This is a two-animal veterinary case report and should be read as such.

Hypoglycemia following median arcuate ligament syndrome surgery

A case is presented of a patient who developed symptomatic hypoglycemia after surgical treatment for median arcuate ligament syndrome, with predominantly postprandial hypoglycemia after higher-carbohydrate meals. Clinical findings indicated postprandial hyperinsulinemic hypoglycemia [11].

Macronutrient boluses within a low-carbohydrate diet

A randomized crossover study examined acute postprandial endocrine and glycemic kinetics following individual macronutrient boluses in participants adapted to a low-carbohydrate diet, a state the authors describe as producing distinct metabolic adaptations [9].

Continuous glucose monitoring as a precision tool beyond diabetes

A hypothesis-generating narrative review considers CGM as a candidate precision tool for cardiovascular prevention and healthy longevity, noting that subclinical glucose dysregulation contributing to vascular aging is undetectable by conventional screening in apparently healthy individuals, and that postprandial excursions occur even within the normal glycemic range [12].

Comparison of study designs

Compound or intervention	Population or model	CGM role	Design
Dorzagliatin vs linagliptin	T2DM with eGFR <45 mL/min/1.73 m²	Run-in monitoring	Randomized, active-controlled [1]
Insulin glargine once vs twice daily	Pregnant patients, pregestational diabetes	Primary outcome tracking	Randomized [4]
Metformin withdrawal	Adults with metabolic syndrome	Glucose control assessment	Clinical trial, 14-day interruption [6]
Accu-Chek SmartGuide plus Predict App	Type 1 or insulin-treated type 2 diabetes	Intervention under test	Controlled pre-post [7]
Time-restricted eating	Overweight or obese adults post weight loss	Not specified in protocol summary	Two-arm randomized, six regions [8]
Cabergoline	Two cats with diabetes and Cushing syndrome	Diabetes management	Veterinary case report [10]

If you are reading this for personal health reasons

The materials described on this page are supplied for laboratory research use only. We do not provide dosing information, medical guidance or treatment advice of any kind. Anyone considering a compound for their own use should speak to a licensed clinician.